Human papillomavirus-related diseases in HIV-infected individuals

PURPOSE OF REVIEWTo present recent publications in human papillomavirus-associated diseases and their relationship to HIV-infected patients. RECENT FINDINGSStudies assessing geographic variations in human papillomavirus types and prevalence in cervical dysplasia and cancer in HIV-infected women sugg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current opinion in oncology 2008-09, Vol.20 (5), p.541-546
Hauptverfasser: Stier, Elizabeth A, Baranoski, Amy S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PURPOSE OF REVIEWTo present recent publications in human papillomavirus-associated diseases and their relationship to HIV-infected patients. RECENT FINDINGSStudies assessing geographic variations in human papillomavirus types and prevalence in cervical dysplasia and cancer in HIV-infected women suggest that although human papillomavirus types 16 and 18 dominate, multiple other human papillomavirus types may play a role in carcinogenesis. Anal dysplasia and cancer incidence continues to rise in the highly active antiretroviral therapy era; however, data on outcomes following therapy for anal dysplasia (infrared coagulator, high-resolution anoscopy-guided ablation) and anal cancer (chemoradiation and possibly intensity-modulated radiation therapy) have been encouraging. Oral human papillomavirus may be associated with lower genital tract human papillomavirus infection and may have implications in the development of oropharyngeal cancer. SUMMARYAs HIV-infected patients in the highly active antiretroviral therapy era continue to have high rates of cervical and anal cancer, it is important to continue screening efforts and treatment of preinvasive disease. Treatment options for anal dysplasia and anal cancer in HIV-infected individuals are expanding and may lead to decreased morbidity and mortality. Trials assessing safety and immunogenicity of the human papillomavirus quadrivalent vaccine in people with HIV have started enrollment, and if successful, may prevent many human papillomavirus-associated cancers.
ISSN:1040-8746
1531-703X
DOI:10.1097/CCO.0b013e3283094ed8